- Patients with STEMI and onset of symptoms within 12 hours if PCI delay > 120 minutes (class I)
- Patients with STEMI and onset of symptoms between 12-24 hours if continued symptoms or ECG changes and PCI unavailable (class IIa)
Door to needle time <30 minutes
Not indicated for patients with ST depression
Absolute contraindications for fibrinolytic use in STEMI include the following:
[16]
Prior intracranial hemorrhage (ICH)
Known structural cerebral vascular lesion
Known malignant intracranial neoplasm
Ischemic stroke within 3 months
Suspected aortic dissection
Active bleeding or bleeding diathesis (excluding menses)
Significant closed head trauma or facial trauma within 3 months
Intracranial or intraspinal surgery within 2 months
Severe uncontrolled hypertension (unresponsive to emergency therapy)
For streptokinase, prior treatment within the previous 6 months
Relative contraindications for fibrinolytic use in STEMI include the following:
[16]
History of chronic, severe, poorly controlled hypertension
Significant hypertension on presentation (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg
Traumatic or prolonged (> 10 minutes) cardiopulmonary resuscitation (CPR) or major surgery less than 3 weeks previously
History of prior ischemic stroke not within the last 3 months
Dementia
Recent (within 2-4 weeks) internal bleeding
Noncompressible vascular punctures
Pregnancy
Active peptic ulcer
Current use of an anticoagulant (eg,
warfarin sodium) that has produced an elevated international normalized ratio (INR) higher than 1.7 or a prothrombin time (PT) longer than 15 seconds